Abbott announced that new data on its core vascular and cardiac devices will be presented at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium (7 – 11 November, San Francisco, USA).
The most recent data on two key investigational devices: the MitraClip system for mitral valve repair and the Absorb bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease will be presented. One-year data for the Xience Prime everolimus eluting coronary stent system, recently approved by the FDA will also be featured. In addition, long-term data will be presented from the SPIRIT III and SPIRIT IV trials comparing Abbott’s Xience V everolimus eluting coronary stent system for coronary artery lesions to the Taxus Express paclitaxel-eluting coronary stent system.
“Innovation drives our business and we look forward to new data at TCT for the advanced technologies we are developing to improve patient care, such as the MitraClip system and the Absorb bioresorbable scaffold,” said Robert B Hance, senior vice president, Vascular, Abbott. “In addition, data will be presented on our next-generation Xience Prime stent, which incorporates the best of our Xience technology with design enhancements for use in treating challenging lesions, making it an important addition to our Xience family of drug eluting stents.”
